Skip to content
Dr. Heather Fehling Ph.D.Jan 30, 2020 11:03:00 AM1 min read

Epigenetics: Why the Science is Important & What CRL Needs from You

Epigenetic testing is a critical part of CRL’s approach to innovative science. Read below to learn about how epigenetic testing can contribute to more informed life insurance underwriting. At the end of the article is a short survey requesting client feedback to advise epigenetic research at CRL in 2020.

Epigenetics has become a prominent topic among life insurance companies. The emerging science of epigenetics describes how lifestyle (e.g. smoking, drinking, exercise) and environment influence gene expression over time. Although our genetic blueprint itself is fixed, measurable epigenetic changes affect the expression of those genes and have significant impact on our health and well-being.

Whether epigenetic testing is a genetic test and subject to the regulations surrounding the use of genetics for health insurance underwriting is under debate. The Greek word “epi” translates to “above” or “on top of,” meaning these are external modifications that sit on top of the DNA. They are not DNA sequences themselves; rather, they are chemical tags that influence how genes are turned on or off.

An epigenetic pattern can act as a footprint for detecting behaviors based on changes in these chemical tags. Early studies have shown that epigenetic patterns change with mortality risk, aging, smoking behavior (including current use, past use, pack-year history), and alcohol use. Each of these associations is based on a unique combination of epigenetic sites, and exactly how strong and reliable these associations are is actively being researched.

The CRL team has investigated epigenetic tests from leading providers over the past year. As we define future studies, we are interested in our clients’ feedback on epigenetic testing, applications of such, and potential pilot studies. Using this information, we will tailor additional studies and present summary data to clients to help them make informed decisions regarding epigenetic testing.

Please help us (and yourselves) by participating in the Epigenetic Survey linked here.

About the Author

Dr. Fehling has been with CRL since 2008 and is a certified High Complexity Laboratory Director by the American Board of Bioanalysis (ABB). Dr. Fehling serves as the Laboratory Director for CRL’s Molecular Diagnostics/Esoteric Laboratory. More broadly, Dr. Fehling provides scientific leadership across all business units at CRL with her extensive experience in laboratory management, new assay development, and business development.

  
Dr. Heather Fehling Ph.D.Jan 30, 2020, 4:02:00 PM1 min read

Epigenetics White Paper on Technology & Innovation: CRL Doctor Expertise

Dr. Heather Fehling, Chief Scientific Officer of Molecular Diagnostics at CRL, was honored to join the Society of Actuaries ...
Start Reading
Dr. Michael Fulks MDOct 24, 2024, 4:45:20 PM4 min read

Epigenetics suggests vaping may be almost as bad as smoking!

Dr. Michael Fulks reviews a recent study revealing the epigenetic changes to DNA from both smokers and vapers, challenging the ...
Start Reading
CRL Insurer Services TeamApr 10, 2024, 8:25:00 PM1 min read

Fentanyl Testing for Life Insurance Applicants

Start Reading